ONESOURCE SPECIALTY PHARMA
|
ONESOURCE SPECIALTY PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -6.44 | -1.57 | -97.55 | -199.46 | -76.14 |
| CEPS(Rs) | 17.91 | 22.42 | -72.17 | -87.27 | -15.39 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 508.17 | 512.83 | 96.71 | 194.39 | 333.49 |
| Tax Rate(%) | 19.75 | 74.23 | - | - | 0.11 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.01 | 32.10 | -51.33 | -415.06 | -3.13 |
| EBIT Margin(%) | 2.11 | 6.87 | -160.69 | -950.82 | -41.67 |
| Pre Tax Margin(%) | -6.41 | -4.64 | -212.71 | -1,073.63 | -77.94 |
| PAT Margin (%) | -5.14 | -1.20 | -212.71 | -1,073.63 | -77.86 |
| Cash Profit Margin (%) | 14.31 | 17.76 | -168.34 | -903.98 | -36.45 |
| Performance Ratios | |||||
| ROA(%) | -0.94 | -0.39 | -22.05 | -18.68 | -4.09 |
| ROE(%) | -1.26 | -0.55 | -62.66 | -46.39 | -9.86 |
| ROCE(%) | 0.44 | 2.61 | -21.41 | -19.43 | -2.46 |
| Asset Turnover(x) | 0.18 | 0.33 | 0.10 | 0.02 | 0.05 |
| Sales/Fixed Asset(x) | 0.21 | 0.37 | 0.12 | 0.03 | 0.09 |
| Working Capital/Sales(x) | -89.50 | -52.77 | -0.38 | -0.06 | -0.43 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 4.71 | 2.70 | 8.06 | 39.06 | 10.86 |
| Receivable days | 140.79 | 59.60 | 62.70 | 129.47 | 67.33 |
| Inventory Days | 75.94 | 21.38 | 153.27 | 1,926.33 | 784.45 |
| Payable days | 225.76 | 107.62 | 455.14 | 1,407.02 | - |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | 82.21 | 77.95 | - | - | - |
| Price/Book(x) | 2.90 | 3.41 | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 12.70 | 14.17 | 2.94 | 19.65 | 7.70 |
| EV/Core EBITDA(x) | 56.55 | 42.30 | -6.02 | -4.82 | -2,930.49 |
| EV/EBIT(x) | 597.37 | 206.27 | -1.83 | -2.07 | -18.49 |
| EV/CE(x) | 2.54 | 3.08 | 0.53 | 0.47 | 0.46 |
| M Cap / Sales | 11.87 | 13.84 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -1.61 | 740.43 | 344.07 | -69.80 | - |
| Core EBITDA Growth(%) | -34.04 | 676.08 | 46.82 | - | - |
| EBIT Growth(%) | -69.55 | 135.93 | 24.95 | -589.20 | - |
| PAT Growth(%) | -327.08 | 95.27 | 12.02 | -316.48 | - |
| EPS Growth(%) | -310.00 | 98.39 | 51.09 | -161.96 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.22 | 0.13 | 1.45 | 1.07 | 1.14 |
| Current Ratio(x) | 0.99 | 0.98 | 0.28 | 0.26 | 0.63 |
| Quick Ratio(x) | 0.69 | 0.83 | 0.26 | 0.11 | 0.29 |
| Interest Cover(x) | 0.25 | 0.60 | -3.09 | -7.74 | -1.15 |
| Total Debt/Mcap(x) | 0.08 | 0.04 | - | - | - |
Compare Financial Ratios of peers of ONESOURCE SPECIALTY PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ONESOURCE SPECIALTY PHARMA | ₹17,591.5 Cr | 1.3% | -1.1% | -16.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
ONESOURCE SPECIALTY PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ONESOURCE SPECIALTY PHARMA | 1.3% |
-1.1% |
-16.4% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses
